kamada
provides
update
supply
takeda
kamada
expects
receive
million
revenues
sales
takeda
takeda
minimum
commitment
pursuant
existing
supply
agreement
kamada
projects
royalties
takeda
range
million
million
per
year
kamada
reiterates
total
revenues
guidance
million
million
rehovot
israel
globe
newswire
kamada
nasdaq
kmda
tase
biopharmaceutical
company
today
announced
following
recent
discussions
takeda
expects
receive
approximately
million
revenues
supply
takeda
previously
indicated
agreement
takeda
provided
supply
range
pursuant
kamada
revenues
sales
glassia
takeda
projected
million
million
supply
range
included
agreement
provide
flexibility
takeda
address
potential
changes
expected
timeline
completion
planned
transition
glassia
manufacturing
based
recent
discussions
takeda
planned
transition
glassia
manufacturing
plant
advancing
expected
said
amir
london
kamada
chief
executive
officer
takeda
anticipates
glassia
demand
kamada
exceed
minimum
commitment
supply
agreement
expected
generate
million
revenue
kamada
company
prepared
make
necessary
adjustments
plant
costs
align
manufacturing
plan
future
continue
intensively
explore
business
development
opportunities
would
time
mitigate
effects
planned
transition
manufacturing
takeda
added
london
opportunities
funded
strong
cash
position
along
organic
commercial
growth
existing
products
portfolio
distributed
products
israel
expected
future
royalty
payments
takeda
contract
manufacturing
fda
approved
commercialized
specialty
igg
product
well
continued
advancement
development
igg
product
candidate
advancing
clinic
expected
contribute
future
growth
concluded
london
based
agreement
takeda
upon
initiation
sales
glassia
manufactured
takeda
kamada
receive
royalty
payments
rate
net
sales
august
rate
thereafter
minimum
million
annually
years
although
transition
agreement
royalties
phase
result
reduction
kamada
revenue
takeda
based
current
glassia
sales
forecasted
future
growth
kamada
projects
receiving
royalties
takeda
range
million
million
per
year
kamada
kamada
company
commercial
stage
biopharmaceutical
company
focused
orphan
indications
existing
marketed
product
portfolio
product
pipeline
company
uses
proprietary
platform
technology
extraction
purification
proteins
human
plasma
produce
antitrypsin
aat
liquid
form
well
immune
globulins
company
flagship
product
first
liquid
intravenous
aat
product
approved
fda
company
markets
glassia
strategic
partnership
takeda
pharmaceuticals
company
limited
countries
local
distributors
company
second
leading
product
rabies
immune
globulin
human
prophylaxis
rabies
infection
kamrab
fda
approved
marketed
brand
name
strategic
partnership
kedrion
addition
glassia
kedrab
company
product
line
four
pharmaceutical
products
administered
injection
infusion
marketed
distributors
countries
including
israel
russia
brazil
india
countries
latin
america
asia
company
products
development
including
inhaled
formulation
aat
treatment
aat
deficiency
addition
company
intravenous
aat
development
indications
gvhd
prevention
lung
transplant
rejection
company
initiated
development
plasma
derived
immunoglobulin
igg
product
potential
treatment
coronavirus
disease
company
leverages
expertise
presence
protein
therapeutics
market
distributing
complementary
products
israel
manufactured
third
parties
fimi
opportunity
fund
leading
private
equity
investor
israel
company
lead
shareholder
beneficially
owning
approximately
outstanding
ordinary
shares
cautionary
note
regarding
statements
release
includes
statements
within
meaning
section
securities
exchange
act
amended
safe
harbor
provisions
private
securities
litigation
reform
act
statements
statements
historical
facts
including
statements
regarding
expectation
various
business
development
opportunities
funded
strong
cash
position
along
organic
commercial
growth
existing
products
portfolio
distributed
products
israel
expected
future
royalty
payments
takeda
together
contract
manufacturing
fda
approved
commercialized
specialty
igg
product
investigational
igg
product
time
contribute
kamada
future
growth
kamada
projecting
receive
royalties
takeda
range
million
million
per
year
kamada
reiterating
total
revenues
guidance
million
million
statements
based
kamada
current
knowledge
present
beliefs
expectations
regarding
possible
future
events
subject
risks
uncertainties
assumptions
actual
results
timing
events
could
differ
materially
anticipated
statements
result
several
factors
including
limited
continued
evolvement
pandemic
scope
effect
duration
availability
sufficient
raw
materials
required
maintain
manufacturing
plans
effects
pandemic
related
government
mandates
availability
adequate
levels
required
maintain
manufacturing
plans
disruption
supply
chain
due
pandemic
continuation
inbound
outbound
international
delivery
routes
potential
negative
effects
relating
kamada
manufacturing
plant
associated
reduced
manufacturing
takeda
ability
offset
significant
revenue
loss
associated
glassia
manufacturing
transitioning
takeda
continued
demand
kamada
products
including
glassia
kedrab
market
distribution
segment
related
products
israel
financial
conditions
company
customer
suppliers
services
providers
ability
obtain
regulatory
approval
clinical
trials
hyperimmune
igg
product
ability
continue
enrollment
pivotal
phase
innovaate
clinical
trial
kamada
ability
manage
operating
expenses
additional
competition
markets
kamada
competes
regulatory
delays
prevailing
market
conditions
impact
general
economic
industry
political
conditions
israel
otherwise
statements
made
herein
speak
date
announcement
kamada
undertakes
obligation
update
publicly
statements
reflect
subsequent
events
circumstances
except
otherwise
required
law
contacts
chaime
orlev
chief
financial
officer
ir
bob
yedid
lifesci
advisors
llc
bob
